Celerion is committed to swift, exceptional clinical research through translational medicine. Every day, we use our experience, agility, and innovative research strategies to help get drugs to market faster.

Celerion is seeking a Full-time overnight shift Research Nurse to assist with our clinical research trials. This is a dynamic role working with a healthy population offering the ability to learn about clinical research and see the drug development process at work.

Are you looking for an opportunity that will make a difference in the future of health care? If so, we can't wait to meet you. Do you want to learn more?

Responsibilities

• You will be responsible for performing scheduled events according to the study protocol.
• You will work directly with study managers to successfully ensure a successful trial.
• You will work with participants in the research process, under our care, doing vital sign checks, ECGs, blood draws and telemetry monitoring.
• You will also identify and report adverse events to assist in the clinical research process.

Qualifications

• You will have a current NE RN or LPN license and clinical assessment skills
• Your ACLS certification is a plus
• Strong computer and documentation skills

Shift

Availability for 4 x 10hrs shifts from 1900-0700.

Ability to work one weekend per month

Celerion Values: Integrity Trust Teamwork Respect

Celerion is an Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, age, sexual orientation, gender identity, genetic information, marital status, qualified protected veteran status, or disability.

We may use artificial intelligence (AI) tools to support parts of the hiring process, such as reviewing applications, analyzing resumes, or assessing responses. These tools assist our recruitment team but do not replace human judgment. Final hiring decisions are ultimately made by humans. If you would like more information about how your data is processed, please contact us.